ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada [Yahoo! Finance]
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Yahoo! Finance
drugs Nexletol (bempedoic acid) and Nexlizet as a treatment to reduce low-density lipoprotein cholesterol or LDL-C (bad cholesterol) and cardiovascular risk. Nexlizet is a combination of bempedoic acid and ezetimibe. Shares of the company were up 10.7% on Dec. 2 following the announcement of the news. ESPR stock has increased 3.6% so far this year against the industry's decline of 5.2%. Image Source: Zacks Investment Research Nexletol and Nexlizet are approved for treating elevated LDL-C and cardiovascular risk reduction in the United States and Europe. The drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan) in partnership with Daiichi Sankyo. In March 2024, the FDA approved label expansions for Nexletol tablets and Nexlizet tablets to include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients – based on positive data from the cardiovascular outcomes study study — CLEAR.
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development [Yahoo! Finance]Yahoo! Finance
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate DevelopmentGlobeNewswire
- 3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 [Yahoo! Finance]Yahoo! Finance
- BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/24 - Beat
IMCR
Sec Filings
- 1/3/25 - Form 4
- 1/2/25 - Form 8-K
- 11/14/24 - Form SC
- IMCR's page on the SEC website